Cargando…
The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer
Background: Docetaxel is the first-line treatment for castration-resistant prostate cancer (CRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminishes its efficacy in high-dose monotherapy. YK-4-279 is a small molecule inhibitor of ETV1 tha...
Autores principales: | Yu, Lin, Wu, Xiaofeng, Chen, Min, Huang, Huarong, He, Yan, Wang, Huaqian, Li, Dongli, Du, Zhiyun, Zhang, Kun, Goodin, Susan, Zheng, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436478/ https://www.ncbi.nlm.nih.gov/pubmed/28553168 http://dx.doi.org/10.7150/ijms.18382 |
Ejemplares similares
-
YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion
por: Rahim, Said, et al.
Publicado: (2011) -
Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
por: Huang, Huarong, et al.
Publicado: (2015) -
Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1
por: Barber-Rotenberg, Julie S., et al.
Publicado: (2012) -
The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations
por: Xue, Junyu, et al.
Publicado: (2021) -
Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer
por: Jiang, Sen, et al.
Publicado: (2018)